ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enliven Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$38.70+1.38 (+3.70%)
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -232.4% | -27.0% | |
| Return on assets | – | -66.6% | -25.9% | |
| Current ratio | – | 14.47 | 28.66 | |
| Diluted shares | – | 2M | 57M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Enliven Therapeutics generated $283.61M from operations and spent $975.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$283.61M
Used
$975.00K
Capital expenditure$975.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$103.69M
- Cash generatingOperating cash flow above zero-$70.30M
- Return on assets improvedROA up on the prior year-32.7% → -31.8%
- Earnings backed by cashOperating cash flow above net income-$70.30M vs -$103.69M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose19.99 → 28.66
- No dilutionShare count did not rise47M → 57M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –